Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion (Nasdaq: BMEA) will report results from its Phase I GLP-131 study of BMF-650 on October 13, 2026.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA) will report results from its Phase I GLP-131 study of BMF-650 on October 13, 2026. BMF-650 is an investigational oral small-molecule drug designed to activate the GLP-1 receptor. Management will discuss the results on a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) that day. The webcast will be available through the company’s Investors and Media website section, with a replay following the event.

Argus 15 min delay 22 alerts

+9.56% vs previous close $1.49 last price 3.2x rel. volume Open Argus

Details

Market Reaction – BMEA

+13.0% Peak in 18 min

$1.35 – $1.65 Day Range

$108.00M Market Cap

On Oct 12, the day this news came out, the latest delayed price for BMEA is 9.56% above the previous close. Argus tracked a peak move of +13.0% during the session. Our momentum scanner has recorded 22 alerts for this stock so far that day. The latest delayed price is $1.49. Relative volume is very high at 3.2x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Scheduled Phase I results: October 13, 2026

Scheduled Phase I results: October 13, 2026; GLP-131 study evaluating BMF-650

Key Terms

phase i, glp-1 receptor agonist

2 terms

phase i medical

"report results from its Phase I GLP-131 clinical study"

A Phase I clinical trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety and finding an appropriate dose by studying a small group of volunteers or patients. Investors watch Phase I results because they reveal early signs of safety, tolerability and how the body handles the treatment—information that helps gauge development risk and the likelihood and timing of later, larger trials that drive a drug’s value, much like a test drive reveals whether a prototype is worth further investment.

glp-1 receptor agonist medical

"next-generation oral small-molecule GLP-1 receptor agonist"

A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/12/2026 - 04:30 PM EDT

Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT)

SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that it will report results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational next-generation oral small-molecule GLP-1 receptor agonist, on Tuesday, October 13, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the results.

Conference Call and Webcast Details

Biomea’s management will host a conference call and webcast on Tuesday, October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT). The live webcast will be accessible through the Investors and Media section of the Company’s website at https://investors.biomeafusion.com/news-events/events. A replay will be available on the Company’s website following the event.

About Biomea Fusion

Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity and related conditions. We aim to cure.

Visit us at www.biomeafusion.com and follow us on LinkedIn, X and Facebook.

Contact:
Meichiel Jennifer Weiss
Senior Director of Investor Relations and Corporate Development
ir@biomeafusion.com

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist